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In general, metastases to the small intestine are rare, and mostly occur in melanoma. CCR9 has been shown to be
the principal chemokine receptor for the thymus expressed chemokine (TECK), a chemokine selectively expressed
in the small intestine and thymus. Here we show that CCR9 is highly expressed on melanoma cells and all
melanoma cell lines isolated from small intestinal metastases, and on a proportion of cell lines from other sites.
Only melanoma cells and cell lines from small intestinal metastases, however, were responsive to the CCR9 ligand
TECK, as assessed by receptor downregulation and by actin polymerization. CCR9 expression was also found on
the adenocarcinoma cell line CaCo-2 expressing characteristics of enterocytic differentiation, but not on any other
cell line isolated from colorectal, breast, and lung cancer. Our data provide evidence that the aberrant functional
cell surface expression of an organ-speciﬁc chemokine receptor is associated with metastasis to this site. The
regulation of receptor function seems to be a critical step in the metastatic process.
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Neoplasms of the small intestine are rare, representing only
2%–5% of gastrointestinal tumors. Most of them are of
metastatic origin and melanoma is the most common tumor
metastatic to the small intestine (Bender et al, 2001; Gill
et al, 2001). Approximately 5% of melanoma patients
develop clinically overt metastases to the small intestine,
but there are reports describing the presence of small
intestinal metastases in up to 60% of melanoma patients
postmortem (Blecker et al, 1999). The small intestine is the
most common site of metastatic melanoma in the gastro-
intestinal tract (Das Gupta et al, 1964).
Recent findings indicate that chemokines and their
receptors are important in determining the metastatic
destination of tumor cells. The expression of CXCR4 and
CCR7 was found in a variety of human cancer cell lines, and
evidence for their role in organ-specific metastasis comes
from various animal models (Muller et al, 2001; Wiley et al,
2001; Murakami et al, 2002; Zeelenberg et al, 2003). The
ligand of CXCR4, SDF-1, is expressed at high levels in
various organs, including the lung, liver, and lymph nodes,
which are frequently involved in tumor metastases. Blocking
of CXCR4 function was shown to reduce or completely
block metastasis of breast and colon cancer cells to the
liver, lung, and lymph nodes in murine models (Muller et al,
2001; Zeelenberg et al, 2003). Conversly, the transfection of
CCR7, mediating migration to the lymph node chemokine
CCL21, into tumor cells increased their metastasis to lymph
nodes (Wiley et al, 2001). An association could be shown for
CCR7 expression on the tumor cells and lymph node
metastasis in gastric cancer patients (Mashino et al, 2002).
Histological studies in tumor patients on the association
between chemokine receptor expression and organ-speci-
fic metastases are, however, hampered, because chemo-
kine receptors expressed on the surface of tumor cells may
not be functional (Honczarenko et al, 1999; Mitra et al, 2001).
CCR9 is an excellent example of an organ-specific
chemokine receptor, because its ligand TECK is selectively
expressed in the small intestine and thymus (Wurbel et al,
2000). CCR9 was identified as the chemokine receptor
regulating lymphocyte trafficking during T cell development
and in mucosal immunity (Zabel et al, 1999). The expression of
CCR9 has not been reported on tumor cells so far. In one study,
CCR9 expression was analyzed by RT-PCR and no CCR9
mRNA expression was detectable in any of 12 melanoma and
seven breast cancer cell lines analyzed (Muller et al, 2001).
In this study, we assess whether the expression of CCR9
and the responsiveness of tumor cells to the ligand TECK
might be associated with the ability of tumor cells to
metastasize to the small intestine. We therefore analyzed
CCR9 expression and function on melanoma cells and cell
lines generated from metastases to the small intestine and
from various other sites.
Results and Discussion
CCR9 is expressed on melanoma cell lines derived from
the small intestine and other tissues We first analyzed
Abbreviations: CCR, chemokine receptor CC; CXCR, chemokine
receptor CXC; IC IFNg, intracellular interferon gamma; PBMC,
peripheral blood mononuclear cells; TECK, thymus expressed
chemokine
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expression of CCR9 on melanoma cell lines established
from small intestinal metastases from three patients. CCR9
was expressed on all three cell lines (UKBF-Mel 12, MA-Mel
16, UKRV-Mel 18B, Fig 1 and Table I). CCR9 expression
was in the same range as found on the human T cell
leukemia line MOLT-4, which has already been described to
express CCR9 (Youn et al, 2001, Fig 1). We next analyzed 17
melanoma cell lines originating from the skin, soft tissue,
lymph node and CNS metastases, and found CCR9
expression on five of these, including four lymph node
(UKRV-Mel 18A, UKRV-Mel 17, SB Mel, MKR) and one
skin metastasis-derived cell line (UKBF-Mel 19). In one of
these five patients (UKRV-Mel 18A), a small intestinal
metastasis had been diagnosed 7 months later, from which
the cell line UKRV-Mel 18B had been established. In
the remaining four patients, no small intestinal metastases
had become clinically evident. Expression of CCR9 on
melanoma cell lines and origin of melanoma metastases
from the small intestine showed a significant correlation
(p¼0.02, w2-test).
CCR9 expression was also found on the colonic
adenocarcinoma cell line CaCo-2 as shown in Fig 1. This
cell line was reported to be isolated from a primary colonic
tumor, but the cells express characteristics of enterocytic
differentiation (Jumarie and Malo, 1991). In contrast, none
out of 29 human tumor cell lines isolated from various
malignancies including colorectal cancer (n¼ 9), lung
cancer (n¼ 8), breast cancer (n¼3), and leukemia (n¼9)
expressed CCR9 (data not shown). This absence of CCR9
is in accordance with the clinical observation that the
occurrence of small intestinal metastases was reported in
less than 0.5% of patients with lung cancer (Berger et al,
1999), and is very rare in patients with colon cancer, breast
cancer, and leukemia.
Figure 1
Expression of chemokine receptor CCR9 on cell lines, the T cell leukemia cell line MOLT-4 and the adenocarcinoma cell line CaCo-2 as
determined by flow cytometry. Cell lines were stained with CCR9 mAb (shaded) or isotypic control mAb (black line). Results are expressed as
fluorescence intensity.
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CCR9 expression on uncultured melanoma cells iso-
lated from a small intestinal metastases To show that
CCR9 is expressed on tumor cells in vivo, we analyzed
CCR9 expression on a single-cell suspension, which was
generated from a melanoma metastasis resected from the
small intestine. The melanoma cells were stained with the
melanoma marker S100 and CCR9 and analyzed by flow
cytometry. The S100-positive melanoma cells expressed all
CCR9 comparable to the levels seen in the CCR9-positive
melanoma cell lines (Fig 2a).
Expression of CCR7 and CXCR4 on CCR9-positive and
CCR9-negative melanoma cell lines Next we analyzed
the expression of the chemokine receptors CCR7 and
CXCR4 on the melanoma cell lines by flow cytometry. Both
chemokines had been shown to be expressed by a
substantial proportion of melanoma cell lines as detected
by quantitative polymerase chain reaction (Muller et al,
2001). Interestingly, all eight CCR9-positive melanoma cell
lines also expressed CXCR4, while only six of 11 CCR9-
negative melanoma cell lines analyzed were CXCR4-
positive. Tumor cells expressing CXCR4 have an increased
potential to metastasize to various organs and to proliferate
and grow (Muller et al, 2001; Murakami et al, 2002;
Zeelenberg et al, 2003). Thus, the co-expression of CXCR4
found on the CCR9-positive melanoma cells may facilitate
their potential to metastasize. It would be of interest to
investigate whether there is a molecular link between the
acquisition of CXCR4 and CCR9 expression in tumor cells.
In contrast, the lymph node-associated chemokine receptor
CCR7 was not expressed on the three CCR9-positive small
intestinal melanoma cell lines or the one isolated from the
skin, but on three of four CCR9-positive melanoma cell lines
derived from lymph node metastases (Table I).
Melanoma cells express functional CCR9 Chemokine
receptors expressed on normal and malignant cells may not
be functional in response to their specific ligands (Honczar-
enko et al, 1999; Mitra et al, 2001). To determine whether
CCR9 expressed on melanoma cells is functional, the effect
of the ligand TECK was assessed in two independent
assays, namely CCR9 internalization and actin polymeriza-
tion. As shown in Fig 3a and b, the CCR9 ligand TECK is
able to induce a downregulation of CCR9 expression on all
three small intestinal melanoma cell lines (UKBF-Mel 12,
MA-Mel 16, UKRV-Mel 18B) and on the one CCR9-positive
melanoma cell line from a skin metastasis (UKBF-Mel 19),
but not on the other four CCR9-positive melanoma cell lines
derived from lymph node metastases (UKRV-Mel 17, UKRV-
Mel 18A, MKR, SB-Mel). Remarkably, UKRV-Mel 18A
originated from the patient from whom we could establish
the TECK-responsive small intestinal line UKRV-Mel 18B
7 mo later.
Actin polymerization, which is an early event in the
migratory response to chemokines, was studied by staining
of intracellular filamentous actin by FITC-phalloidin. TECK
induced a 1.2–1.6-fold increase in intracellular F-actin in all
three CCR9-positive melanoma cell lines isolated from the
small intestine (UKBF-Mel 12, MA-Mel 16, UKRV-Mel 18B)
(Fig 3a and Table I). Responsiveness to TECK was also
shown for the CCR9-positive melanoma cell suspension
from a small intestinal metastasis (Fig 2b and c). In none of
the five CCR9-positive melanoma cell lines generated from
other sites (UKRV-Mel 18A, UKRV-Mel 17, SB-Mel, MKR,
UKBF-Mel 19) actin rearrangement in response to TECK
could be observed (Fig 3a and b and Table I).
In the CCR9-positive/CCR7-negative small intestinal
melanoma cell lines (UKBF-Mel 12, Ma-Mel 16, UKRV-Mel
18B), no alteration of the actin rearrangement could be
observed in response to the CCR7 ligand CCL21/6Ckine,
which was included as negative control. In contrast, CCL21
induced a more than 2-fold and a 1.2-fold increase in
intracellular F-actin, respectively, in the two CCR7-positive
lymph node-derived cell lines UKRV-Mel 17 and MKR,
showing the general ability of these cell lines to exert a
migratory response after chemokine stimulation. All our cell
lines responded to PMA, which was used as positive
control. The responsiveness towards TECK was not
correlated with the expression level of CCR9 on melanoma
cell lines. The results obtained with the actin polymerization
assay confirm those obtained with the CCR9 downregula-
tion assay showing responsiveness to TECK in all three
CCR9-positive small intestinal melanoma cell lines, but not
Figure2
CCRS expression and function on freshly isolated melanoma cells.
(a) Expression of chemokine receptor CCR9 on a single cell suspension
that was generated from a melanoma metastasis resected from the
small intestine as determined by flow cytometry. Melanoma cells were
identified by staining with the melanoma marker S100 and costained
with CCR9 mAb. (b): CCR9 expression was determined by flow
cytometry after incubation with medium alone (control, upper histo-
gram) or after 45 min of incubation with 1 mg per mL of human TECK
(lower histogram). Melanoma cell lines were extensively washed before
staining with CCR9 mAb (shaded) or isotypic control mAb (black line).
Results are expressed as fluorescence intensity. (c) The relative F-actin
content was determined by flow cytometry in the melanoma cells
without stimulation or after 1 min of stimulation with the CCR9-ligand
TECK, and the CCR7-ligand CCL21/6Ckine and PMA as negative and
positive controls, respectively. Results are expressed relative to the
mean fluorescence intensity of the unstimulated sample.
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in those derived from other sites. Discordant results were
obtained only for the CCR9-positive lymph node cell line
UKBF-Mel 19, which responds to TECK by CCR9 down-
regulation but not by actin polymerization. This shows that
the TECK/CCR9 interaction is intact and results in receptor
internalization, and suggests a block in the downstream
signaling machinery. The unresponsiveness to TECK ob-
served in the other four CCR9-positive cell lines may result
from the inability of TECK to bind to CCR9 due to possible
receptor polymorphisms or mutations or due to an
internalization defect. The lack of ligand-mediated chemo-
kine receptor internalization has also been reported for
CXCR4 expressed on the hepatoma cell line HepG2, in
which the existence of a blocking molecule was hypothe-
sized (Mitra et al, 2001).
Taken together, we provide here a first clinical example of
a strong association between expression of a chemokine
receptor and organ-specific metastasis, but only in case the
intracellular signaling in response to the specific ligand is
functional. The demonstration of non-functional chemokine
receptor CCR9 expression on melanoma cells derived from
metastatic sites other than the small intestine suggests that
expression and regulation of chemokine receptor function-
ality is a two-step process in the development of organ-
specific metastasis.
Materials and Methods
Patients and cell lines Melanoma cell lines had previously been
established in our laboratories from metastatic tissue as described
elsewhere (Schadendorf et al, 1994). MOLT-4 and Caco-2 were
obtained from ATCC (American Type Culture Collection, Rockville,
Maryland) and all cell lines were cultured in RPMI-1640 medium
(Biochrom, Berlin, Germany) supplemented with 10% FCS and
antibiotics. In one patient, a melanoma cell suspension was
analyzed obtained by mechanical disruption and direct freezing of
a resected small intestinal metastasis. The study has been
approved by the Institutional Ethics Committee and informed
consent was obtained from all patients. The study has been
performed in compliance with the Declaration of Helsinki.
Flow cytometry analyses Melanoma cells were detached by a
cell scraper and incubated for 10 min in ice-cold phosphate-
buffered saline (PBS) supplemented with human IgG before
Figure 3
Functionality of CCRS. (a and b) Func-
tionality of CCR9 cell surface expres-
sion as determined by TECK-induced
receptor downregulation or actin poly-
merization on the eight CCR9-positive
melanoma cell lines. CCR9 expression
was determined by flow cytometry after
incubation with medium alone (first line
of A and B) or with 1 mg per mL of the
human CCR9 ligand TECK (second line
of A and B). Melanoma cell lines were
extensively washed before staining with
CCR9 mAb (shaded) or isotypic control
mAb (black line). Results are expressed
as fluorescence intensity. In the third line
of A and B, the relative F-actin content
in CCR9-positive melanoma cell lines
without stimulation (00) and after 1 min of
stimulation with the CCR9-ligand TECK,
the CCR7-ligand CCL21/6Ckine, and
PMA as positive control was measured
after permeabilization and intracellular
staining with FITC-phalloidin. Results
are expressed relative to the mean fluo-
rescence intensity of the unstimulated
sample.
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staining for 15 min with phycoerythrin-conjugated antibodies
against CCR9 and the corresponding isotypic control (R&D
Systems, Wiesbaden, Germany) on ice in the dark. Analysis of
TECK-induced CCR9 downregulation was performed after incuba-
tion of melanoma cells for 40 min with 1 mg per mL TECK (R&D
Systems). Melanoma cells were then extensively washed prior to
staining with CCR9 mAb as previously described (Wiley et al,
2001).
Actin polymerization assay Actin polymerization assay was
performed as previously described (Bleul et al, 1996). Melanoma
cells (1  106 per mL) were detached by a cell scraper and
resuspended in RPMI-1640 medium with 0.5% BSA at 371C and
incubated with either 1 mg per mL of TECK, 200 nM CCL21/6Ckine
(R&D Systems), or 100 ng per mL phorbol myristate acetate (PMA)
(Sigma, Deisenhofen, Germany). After 1 min of incubation, 50 mL of
a solution containing 4  107 mol per liter FITC-labeled phalloidin,
0.5 mg per mL 1-lysophosphatidylcholine (both from Sigma), and
18% formaldehyde in PBS were added to the cell suspension. The
fixed cells were analyzed by flow cytometry on a FACSCalibur, and
all results are plotted relative to the mean fluorescence of the
sample without the addition of chemokines or PMA.
Statistical analysis To test whether there is a significant
difference in the CCR9 expression between melanoma cell lines
generated from the small intestine or other sites, data were
analyzed using w2-test statistics.
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